Leflunomide is generally used for the long-term management of chronic autoimmune joint conditions in adults, playing a role in managing symptoms related to heightened physiological activity. It is considered relevant in conditions characterized by periods of heightened symptoms, such as active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA). The medication is indicated for the management of these conditions.

The drug helps address symptom clusters that may become intense or disruptive, such as joint pain, swelling, tenderness, and persistent stiffness. One significant benefit is providing support that helps ease the overall symptom burden. This benefit supports the patient during difficult episodes by helping maintain a sense of stability when symptoms are more noticeable. It assists with supporting functional stability and is relevant for easing symptomatic discomfort associated with situations where symptoms are more disruptive.

Quick Fact: Relief for Inflammatory Joint Pain
Leflunomide contributes to easing the symptom load linked to chronic inflammation, contributing to day-to-day comfort and assisting with physical function.

Regulatory References

1. European Medicines Agency (EMA) overview

Who Can and Cannot Use Leflunomide

Leflunomide eligibility is strictly defined by regulatory authorities and is based on age, reproductive status, and the functional status of key organs. The medicine is indicated only for adult patients (aged 18 and older) with active rheumatoid arthritis (RA) or active psoriatic arthritis (PsA).

---

Absolute Contraindications

Leflunomide must not be used in the following populations:

• Pregnant and breast-feeding women.
• Women of childbearing potential not using reliable contraception.
• Patients with severe hepatic impairment or significant impairment of liver function.
• Patients with severe immunodeficiency states or serious infections.
• Patients with significantly impaired bone marrow function or severe hypoproteinaemia.

---

Age and Condition Restrictions

Population Group	Regulatory Status
Pediatric Patients (Under 18)	Not recommended; safety and efficacy not established.
Renal Impairment	Contraindicated in moderate to severe renal insufficiency.
Male Patients	Must use effective contraception during treatment.

Interactions with other medicines and products

Leflunomide's interaction profile is primarily defined by its active metabolite, Teriflunomide, which affects several drug elimination pathways. This metabolite is documented as both an inhibitor and an inducer of specific enzymes and transporters, leading to documented alterations in the plasma exposure of co-administered medicines.

---

Contraindicated and Restricted Combinations

Co-administration of Leflunomide with Teriflunomide is officially contraindicated. Specific drug combinations carry formal restrictions; for example, the dose of Rosuvastatin must not exceed 10 mg once daily due to the risk of increased exposure resulting from transporter inhibition. Use is also contraindicated in patients with severe hepatic impairment due to reduced clearance.

---

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Pathway/Agent	Interaction Outcome	Regulatory Classification
CYP2C8, BCRP, OAT3	Increased exposure of substrate medicines	Pharmacokinetic Inhibition
CYP1A2	Decreased exposure of substrate medicines	Pharmacokinetic Induction
Hepatotoxic Drugs / Alcohol	Increased risk of liver injury (Hepatotoxicity)	Additive Risk (Pharmacodynamic)
Oral Contraceptives	Increased plasma exposure (Ethinylestradiol, Levonorgestrel)	Pharmacokinetic
Warfarin	Requires close monitoring of International Normalized Ratio (INR)	Pharmacodynamic

Co-administration with other immunosuppressive or immunomodulating therapies carries a warning for the potential additive risk of myelosuppression. Additionally, live attenuated vaccines are not recommended.

How Лефлуномид Works

The mechanism of action for Лефлуномид is executed by its active metabolite, Teriflunomide, which achieves its effect through specific enzyme inhibition and a resulting selective cellular effect on the immune system.

---

Targeted Blockade of the Pyrimidine Synthesis Pathway

The active metabolite, Teriflunomide, functions as a non-competitive, reversible inhibitor of the mitochondrial enzyme Dihydroorotate Dehydrogenase (DHODH). This molecular action directly blocks a critical, rate-limiting step in the de novo pyrimidine synthesis pathway, which is essential for creating the building blocks of DNA and RNA.

Selective Cytostasis of Activated Lymphocytes

The depletion of pyrimidine nucleotides causes immune cells—specifically the hyperactive T- and B-lymphocytes—to become arrested in the G1 phase of their cell cycle. This action is cytostatic (halts growth) and selective because rapidly proliferating lymphocytes are uniquely dependent on this pathway, leading to a stable reduction in the population of hyperactive immune cells.

Systemic Modulation of Inflammatory Mediators

The controlled proliferation of these key immune cells reduces their numbers, resulting in a crucial secondary effect: a systemic decrease in the production and release of major proinflammatory cytokines such as TNF-alpha and interleukins. This dampening of the systemic inflammatory cascade results in a regulated activity within the targeted physiological pathways.

How to Use Лефлуномид (Leflunomide) — Administration Guidelines

Leflunomide is administered for long-term management and is available as an oral, film-coated tablet in 10 mg and 20 mg strengths. The dosing structure establishes a standardized, once-daily pattern for therapy.

---

Dosing and Administration Schedule

The medicine is taken once daily and may be administered with or without food, as food intake does not significantly affect absorption.

Indication	Phase	Regimen	Max Daily Dose
Rheumatoid/Psoriatic Arthritis	Loading Dose (Optional)	100 mg once daily for 3 days	N/A
Rheumatoid Arthritis (RA)	Maintenance Dose	10 mg to 20 mg once daily	20 mg
Psoriatic Arthritis (PsA)	Maintenance Dose	20 mg once daily	20 mg

Note: The optional loading dose may be omitted to potentially reduce the initial risk of adverse events.

---

Key Procedural Instructions

The tablets must be swallowed whole with a sufficient amount of liquid; the tablets must not be crushed, split, or chewed. If a dose is missed, the next scheduled daily dose should be taken as usual; a double dose should not be taken.

• Age-Group Use: No dosage adjustment is typically required for older adults (over 65 years). Use in patients under 18 years of age is not recommended due to insufficient data on efficacy and safety in the pediatric population.

Лефлуномид: Recent Clinical Evidence

Leflunomide is a disease-modifying antirheumatic drug (DMARD) used primarily for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Clinical evidence is largely based on randomized controlled trials (RCTs) comparing leflunomide monotherapy to placebo or other conventional DMARDs.

Efficacy in Rheumatoid and Psoriatic Arthritis

• Rheumatoid Arthritis (RA): Trials lasting up to two years have shown that leflunomide monotherapy is comparable to methotrexate (MTX) in its effect on clinical measures and the rate of radiographic joint damage progression. Studies also explored the use of leflunomide in combination with MTX for patients who had an incomplete response to MTX alone.
• Psoriatic Arthritis (PsA): Research, including multinational, placebo-controlled trials, indicated that leflunomide was associated with significant improvement in the Psoriatic Arthritis Response Criteria (PsARC) and skin involvement (psoriasis) compared to placebo. One recent randomized trial suggested comparable effectiveness to MTX in treating moderate to severe plaque psoriasis.

---

Key Findings Summary

Outcome Evaluated	Result (Compared to Placebo/Other DMARDs)
Slowing Joint Damage	Comparable to Methotrexate (MTX) in clinical trials.
Combination Therapy	Used in combination with MTX or certain biologic DMARDs; explored for patients with partial response to monotherapy.

---

Safety and Adverse Event Profile

Leflunomide is associated with a risk of liver injury, including rare cases of severe liver failure, which has led to required patient monitoring. Commonly observed adverse events in clinical trials included diarrhea, nausea, rash, and reversible hair thinning (alopecia). Regular monitoring of liver function is necessary during treatment. Studies have also explored its use as a glucocorticoid-sparing agent in conditions like Giant Cell Arteritis (GCA), though higher-quality trials are still needed to clarify its role and safety in this context.

Common questions about Лефлуномид (FAQ)

---

Q: How does Leflunomide conceptually differ from Methotrexate as a DMARD?

A: Official information indicates that Leflunomide's active metabolite, Teriflunomide, works as an inhibitor of the enzyme Dihydroorotate Dehydrogenase (DHODH). This specific action interferes with the process of pyrimidine synthesis within lymphocytes, which are key immune cells. This mechanism of action is distinct from that of other conventional disease-modifying antirheumatic drugs (DMARDs).

Q: How often are blood tests required while taking Leflunomide?

A: Official recommendations call for checking liver function and blood counts at baseline, or before treatment begins. Testing is then typically required again within the first one to two months, and subsequently, generally every three to four months during the maintenance phase of treatment. Monitoring is typically required and serves to detect potential changes early.

Q: Why might Leflunomide affect blood cell counts?

A: Leflunomide’s active metabolite works by inhibiting the synthesis of pyrimidines, which are essential building blocks for DNA and RNA. This process suppresses the proliferation of rapidly dividing cells, including the hyperactive immune cells targeted by the drug. Since various blood cells also divide rapidly, this mechanism may potentially contribute to observed changes in their quantity.

Q: How long does Leflunomide remain in the body after stopping treatment?

A: The active metabolite of Leflunomide has a long half-life, which regulatory data estimates to be approximately 14 to 18 days. Because of this long duration, the metabolite can remain in the body for many weeks or even months after a patient stops taking the medication. This prolonged presence is a factor noted in its pharmacological profile.

Q: What is the Leflunomide elimination (washout) procedure, and when is it needed?

A: The elimination procedure is a process designed to quickly remove the active metabolite from the body. The procedure uses a specific type of medication, such as cholestyramine or activated charcoal. This procedure may be necessary if a patient experiences serious side effects or before a woman plans a pregnancy.

Q: Which vaccines can and cannot be received during treatment with Leflunomide?

A: Official documents indicate that live attenuated vaccines are not recommended due to the immunosuppressive effect of the drug. Inactivated or non-live vaccines, such as the annual flu shot, may be considered.

Q: Why does Leflunomide have an FDA black box warning regarding the liver?

A: Leflunomide carries an official 'Boxed Warning' from regulatory agencies, which is a significant safety precaution. This risk is noted, and official guidelines mandate routine liver function monitoring throughout the course of treatment. The warning exists because of the risk of serious liver damage, which includes rare cases of acute liver failure.

Q: What is known about the long-term effects of taking Leflunomide?

A: Clinical studies have examined the long-term use of the drug, with follow-up data extending up to five years. In these studies, the improvement in functional measures and efficacy achieved in the first year was maintained. However, no new types of serious adverse events were reported during the extended period of treatment.

Q: Can Leflunomide be used to treat other types of arthritis besides rheumatoid and psoriatic?

A: Official regulatory agencies state that Leflunomide is indicated only for the treatment of active rheumatoid arthritis and active psoriatic arthritis. The drug's use for other conditions, such as Giant Cell Arteritis, is not supported by the current official indications.

Q: What are the general expectations for how soon Leflunomide will start working?

A: The onset of clinical effect is typically not immediate. Without an initial loading dose, official pharmacological information indicates that it takes about two months of regular dosing to reach stable concentrations of the active metabolite in the blood plasma.

Q: How long does it take to achieve the full therapeutic effect of Leflunomide?

A: After the active metabolite reaches a stable concentration, which occurs after approximately two months, the full manifestation of the therapeutic action may take several additional months. The full manifestation of the therapeutic action is based on the individual's clinical course.

Q: Can Leflunomide cause weight loss?

A: Weight loss is not listed as a direct side effect in the official frequency classifications. However, related adverse events like nausea and loss of appetite, which are commonly reported, may potentially lead to a decrease in weight. Unexplained or significant weight changes are observations to note regarding one's health status.

Q: Is peripheral neuropathy associated with Leflunomide?

A: Damage to the nerves in the extremities, known as peripheral neuropathy, has been reported as a serious adverse event while taking Leflunomide.

Q: What are the signs of a serious skin reaction associated with taking Leflunomide?

A: Serious skin reactions may begin with non-specific flu-like symptoms. These can quickly be followed by the appearance of blisters and peeling skin. The development of painful sores on mucous membranes is also a key sign of severe skin reactions.

Q: Can non-steroidal anti-inflammatory drugs (NSAIDs) be taken with Leflunomide?

A: Official drug interaction information suggests that taking non-steroidal anti-inflammatory drugs (NSAIDs) concurrently with Leflunomide may increase the risk of liver damage. More frequent monitoring of liver function is noted as a potential necessity if they are taken concurrently.

Q: What factors may increase the risk of adverse events while taking Leflunomide?

A: The risk of adverse events may be elevated by certain factors. These include the simultaneous use of other medications that are potentially toxic to the liver, such as Methotrexate. Pre-existing liver disease and the first six months of treatment are also noted in guidelines as factors that can elevate risk.

Q: Is tuberculosis testing required before starting Leflunomide?

A: Official guidelines state that patients should undergo evaluation for active and latent tuberculosis (TB) infection prior to initiating treatment.

Storage Conditions

Leflunomide tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C (86 F). The medication must be kept in its original container and, if supplied in a bottle, the container should be kept tightly closed to maintain product integrity.

Mandatory Protection

The tablets must be protected from moisture, excessive heat, and freezing. Storage in a bathroom or other damp area is prohibited by regulatory labeling. A critical requirement is that the medicine must always be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired Leflunomide tablets must be disposed of in accordance with local requirements for pharmaceutical waste. The product is not on the FDA's flush list and should not be discarded by flushing down the toilet or pouring into a drain. Disposal should follow established local drug take-back programs or household trash procedures, as outlined by regulatory agencies.